Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to test study drug AZD1480 to see how it may work to treat
myeloproliferative diseases. The main purpose of this study is to determine the safety and
tolerability of AZD1480. This is the first time the drug has been given to humans and is
classed as a first time in man study. Its main purpose is to establish a safe dosage of the
drug and provide additional information on any potential side effects this drug may cause.
The study will also assess the blood levels and action of AZD1480 in the body over a period
of time and will indicate whether the drug has a therapeutic effect on myeloproliferative
diseases.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborators:
Gustave Roussy, Cancer Campus, Grand Paris New York City Hoffman Center University of Texas